MARATTO

article · Small

AI‐Guided Design of pH‐ and Redox‐Responsive Lignin@GO@ZIF‐8 Nanocarriers for Targeted Co‐Delivery of 5‐Fluorouracil and Metformin in Prostate Cancer Therapy

Abstract

Prostate cancer therapy is limited by systemic toxicity and inefficient tumor-selective delivery. Here we report a multi-stimuli-responsive nanocomposite, Lignin@GO@ZIF-8, that co-delivers 5-Fluorouracil (5-FU) and metformin and couples pH- and redox-responsive release. We integrate machine learning (ML) to guide formulation: trained on 500 formulation property pairs with cross-validation and a held-out test set, XGBoost achieved the highest predictive performance (R<sup>2</sup> = 0.86-0.89) for drug loading, encapsulation efficiency, and release rate, with influential features including the ZIF-8 fraction, graphene oxide (GO) content, particle size, zeta potential, pH, and glutathione concentration. ML-optimized Lignin@GO@ZIF-8 exhibited improved loading and tunable release relative to pre-optimized controls. In vitro, the platform sustained drug release and produced potent anticancer activity, reducing LNCaP viability to 18 ± 3% at 72 h, while showing low cytotoxicity toward non-malignant cells. These results support a data-driven framework for rational design of multifunctional, stimuli-responsive nanomedicine platforms and may help inform future translational strategies for prostate cancer.

Research topics

  • Nanoplatforms for cancer theranostics
  • Graphene and Nanomaterials Applications
  • Nanoparticle-Based Drug Delivery

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1002/smll.202513085

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.